Rationale and Objectives
Ductal carcinoma in situ (DCIS) hinders imaging detection due to multifocal appearance
and discontinuous growth. Preoperative determination of its extent is therefore challenging.
Aim of this study was to investigate the additional benefit of breast magnetic resonance
imaging (MRI) to mammography (MG) in the diagnosis of DCIS according to size and grading.
Materials and Methods
Retrospective analysis of 295 patients with biopsy-proven, pure DCIS. Mean patient
age was 57.0 years (27–87 years). All patients obtained MG. Additional MRI was performed
in 41.7% (123/295). Mammographic breast density, background parenchymal enhancement
(BPE), tumor size and grading were analysed. Tumor size on MG and MRI were compared
to histopathological size of the surgical specimen.
Results
Mean tumor size was 39.6 mm. DCIS was occult on MG in 24.4% (30/123) and on MRI in
1.6% (2/123). Size was underestimated by 4.6 mm (mean) mammographically. DCIS was
high grade in 54.5% (67/123), intermediate grade in 40.7% (50/123) and low grade in
4.9% (6/123). MG was exact regarding tumor size in low grade DCIS, underestimated
intermediate grade DCIS by 1 mm (median) and high grade DCIS by 10.5 mm. MRI overestimated
low grade DCIS by 1 mm (median), was exact regarding intermediate grade DCIS and underestimated
high grade DCIS by 1 mm. BPE did not influence tumor detection and measurement.
Conclusion
MRI outperforms MG in the detection and size estimation of DCIS and can reduce positive
margin rates.
Key Words
Abbreviations:
ACR (American College of Radiology), BI-RADS (Breast Imaging Reporting and Data System), BPE (benign background parenchymal enhancement), CC (craniocaudal), DCIS (ductal carcinoma in situ), MG (mammography), MLO (mediolateral-oblique), MRI (magnetic resonance imaging), US (ultrasound)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Academic RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications.Semin Diagn Pathol. 1994; 11: 193-198
- Incidence of and treatment for ductal carcinoma in situ of the breast.JAMA. 1996; 275: 913-918
- Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography.Breast Cancer Res Treat. 2017; 166: 843-854
- Recent advances and current controversies in the management of DCIS of the breast.Cancer Treat Rev. 2008; 34: 483-497
- Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.Breast Cancer Res Treat. 2017; 166: 307-314
- Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation.Cancer Lett. 1995; 90: 97-102
- [Prognostic factors in ductal carcinoma in situ].Pathologe. 2006; 27: 326-336
- Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.Cancer. 2001; 91: 1090-1097
- MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study.Lancet. 2007; 370: 485-492
- Added Value of Breast MRI for preoperative diagnosis of ductal carcinoma in situ: Diagnostic Performance on 362 Patients.Clin Breast Cancer. 2017; 17: e127-e134
- Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.Radiology. 2004; 233: 830-849
- Rate of re-excision after breast-conserving surgery for invasive lobular carcinoma.Am Surg. 2013; 79: 1119-1122
- Factors associated with residual disease after initial breast-conserving surgery for ductal carcinoma in situ.Hum Pathol. 2012; 43: 986-993
- Role of ultrasonography in detecting mammographically occult breast carcinoma in women with dense breasts.Radiol Med. 2006; 111: 440-448
- Detection of ductal carcinoma in situ in women undergoing screening mammography.J Natl Cancer Inst. 2002; 94: 1546-1554
- The molecular journey from ductal carcinoma in situ to invasive breast cancer.Cancer. 2008; 112: 2130-2142
- Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ.Lancet. 1990; 335: 519-522
- Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard.AJR Am J Roentgenol. 2004; 183: 1149-1157
- Characterization of pure high-grade DCIS on magnetic resonance imaging using the evolving breast MR lexicon terminology: can it be differentiated from pure invasive disease.Magn Reson Imaging. 2005; 23: 733-738
- Ductal carcinoma in situ: MR imaging-histopathologic correlation.Radiology. 1995; 196: 415-419
- The influence of margin width on local control of ductal carcinoma in situ of the breast.N Engl J Med. 1999; 340: 1455-1461
- MRI of the breast for the detection and assessment of the size of ductal carcinoma in situ.Korean J Radiol. 2007; 8: 32-39
- Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade.Radiology. 2007; 245: 684-691
- Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.Am J Surg. 2006; 192: 520-524
- Value of pre-operative breast MRI for the size assessment of ductal carcinoma in situ.Br J Radiol. 2016; 8920150543
- Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review.Am J Surg. 2009; 198: 262-269
- Repeated surgeries in invasive lobular breast cancer with preoperative MRI: role of additional carcinoma in situ and background parenchymal enhancement.Eur J Radiol. 2017; 90: 181-187
Article info
Publication history
Published online: August 24, 2018
Accepted:
July 23,
2018
Received in revised form:
July 10,
2018
Received:
May 30,
2018
Identification
Copyright
© 2018 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.
